These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32473355)
1. TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. Laine M; Lemesle G; Burtey S; Cayla G; Range G; Quaino G; Canault M; Pankert M; Paganelli F; Puymirat E; Bonello L Am Heart J; 2020 Jul; 225():19-26. PubMed ID: 32473355 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558 [TBL] [Abstract][Full Text] [Related]
3. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361 [TBL] [Abstract][Full Text] [Related]
4. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541 [TBL] [Abstract][Full Text] [Related]
5. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ; Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203 [TBL] [Abstract][Full Text] [Related]
6. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028 [TBL] [Abstract][Full Text] [Related]
7. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients. Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750 [TBL] [Abstract][Full Text] [Related]
8. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Wang HY; Li Y; Xu XM; Li J; Han YL Chin Med J (Engl); 2018 Sep; 131(17):2017-2024. PubMed ID: 30127210 [TBL] [Abstract][Full Text] [Related]
9. Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis. Guo Y; Ge P; Li Z; Xiao J; Xie L Am J Cardiovasc Drugs; 2023 Sep; 23(5):533-546. PubMed ID: 37530990 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066 [TBL] [Abstract][Full Text] [Related]
11. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703 [TBL] [Abstract][Full Text] [Related]
13. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197 [TBL] [Abstract][Full Text] [Related]
14. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Graham CA; Tan MK; Chew DP; Gale CP; Fox KAA; Bagai A; Henderson MA; Quraishi AUR; Déry JP; Cheema AN; Fisher H; Brieger D; Lutchmedial SR; Lavi S; Wong BYL; Cieza T; Mehta SR; Brass N; Goodman SG; Yan AT Heart Vessels; 2022 Aug; 37(8):1291-1298. PubMed ID: 35089380 [TBL] [Abstract][Full Text] [Related]
15. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598 [TBL] [Abstract][Full Text] [Related]
16. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice. Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention. Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R Platelets; 2020; 31(3):337-343. PubMed ID: 31043110 [TBL] [Abstract][Full Text] [Related]
18. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials. Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Sun Y; Li C; Zhang L; Yu T; Ye H; Yu B; Tao M; Jiang J; Yan J; Wang Y; Zeng H; Shen X; Wang DW Atherosclerosis; 2019 Nov; 290():52-58. PubMed ID: 31568962 [TBL] [Abstract][Full Text] [Related]